Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
NCT06099704
·
clinicaltrials.gov ↗
COMPLETED
Status
305
Enrollment
INDUSTRY
Sponsor class
Conditions
Moderate to Severe Atopic Dermatitis
Sponsor
Sanofi
Collaborators
[object Object]